

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 December 2005 (15.12.2005)

PCT

(10) International Publication Number
WO 2005/117887 A1

(51) International Patent Classification⁷: **A61K 31/513**,
31/517, 31/5377, 31/519, 31/4706, A61P 35/00

(21) International Application Number:
PCT/EP2005/005735

(22) International Filing Date: 27 May 2005 (27.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/576,541 3 June 2004 (03.06.2004) US

(71) Applicant (for all designated States except US): **F. HOFF-
MANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse
124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HIGGINS, Brian**
[US/US]; 69-14 Utopia Parkway, Fresh Meadows, NY
11365 (US). **KOLINSKY, Kenneth** [US/US]; 22 Vree-
land Avenue, Bloomington, NJ 07403 (US).

(74) Agent: **KLEIN, Thomas**; Grenzacherstrasse 124,
CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT WITH GEMCITABINE AND AN EGFR-INHIBITOR

(57) Abstract: The present invention provides a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine is used, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practising this invention is the compound erlotinib HCl (also known as TarcevaTM).



WO 2005/117887 A1

TREATMENT WITH GEMCITABINE AND AN EGFR-INHIBITOR

BACKGROUND OF THE INVENTION

5 [1] The present invention is directed to compositions and methods for manufacturing medicaments intended for treating cancer. In particular, the present invention is directed to methods for manufacturing medicaments comprising gemcitabine and an epidermal growth factor receptor (EGFR) kinase inhibitor.

10 [2] Cancer is a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body.

15 [3] A multitude of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer. The most commonly used types of anticancer agents include: DNA-alkylating agents (e.g., cyclophosphamide, ifosfamide), antimetabolites (e.g., methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist), microtubule disrupters (e.g., vincristine, vinblastine, paclitaxel), DNA
20 intercalators (e.g., doxorubicin, daunomycin, cisplatin), and hormone therapy (e.g., tamoxifen, flutamide).

[4] According to the National Cancer Institute, lung cancer is the single largest cause of cancer deaths in the United States and is responsible for nearly 30% of cancer
25 deaths in the country. According to the World Health Organization, there are more than 1.2 million cases worldwide of lung and bronchial cancer each year, causing approximately 1.1 million deaths annually. NSCLC is the most common form of lung cancer and accounts for almost 80 percent of all cases. Treatment options for lung cancer

are surgery, radiation therapy, and chemotherapy, either alone or in combination, depending on the form and stage of the cancer. For advanced NSCLC, agents that have been shown to be active include cisplatin, carboplatin, paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine (e.g. gemzar®), and the EGFR kinase inhibitors gefitinib and erlotinib. Cisplatin-containing and carboplatin-containing combination chemotherapy regimens have been shown to produce objective response rates that are higher than those achieved with single-agent chemotherapy (Weick, J.K., et al. (1991) *J. Clin. Oncol.* 9(7):1157-1162). It has been reported that paclitaxel has single-agent activity in stage IV patients, with response rates in the range of 21% to 24% (Murphy W.K., et al. (1993) *J. Natl. Cancer Inst.* 85(5):384-388). Paclitaxel combinations have shown relatively high response rates, significant 1 year survival, and palliation of lung cancer symptoms (Johnson D.H., et al. (1996) *J. Clin. Oncol.* 14(7):2054-2060). With a paclitaxel plus carboplatin regimen, response rates have been in the range of 27% to 53% with 1-year survival rates of 32% to 54%. However, efficacy of such treatments is such that no specific regimen can be regarded as standard therapy at present.

[5] Over-expression of the epidermal growth factor receptor (EGFR) kinase, or its ligand TGF- α , is frequently associated with many cancers, including breast, lung, colorectal and head and neck cancers (Salomon D.S., et al. (1995) *Crit. Rev. Oncol. Hematol.* 19:183-232; Wells, A. (2000) *Signal*, 1:4-11), and is believed to contribute to the malignant growth of these tumors. A specific deletion-mutation in the EGFR gene has also been found to increase cellular tumorigenicity (Halatsch, M-E. et al. (2000) *J. Neurosurg.* 92:297-305; Archer, G.E. et al. (1999) *Clin. Cancer Res.* 5:2646-2652). Activation of EGFR stimulated signaling pathways promote multiple processes that are potentially cancer-promoting, e.g. proliferation, angiogenesis, cell motility and invasion, decreased apoptosis and induction of drug resistance. The development for use as anti-tumor agents of compounds that directly inhibit the kinase activity of the EGFR, as well as antibodies that reduce EGFR kinase activity by blocking EGFR activation, are areas of intense research effort (de Bono J.S. and Rowinsky, E.K. (2002) *Trends in Mol. Medicine* 8:S19-S26; Dancey, J. and Sausville, E.A. (2003) *Nature Rev. Drug Discovery* 2:92-313). Several studies have demonstrated or disclosed that some EGFR kinase inhibitors can improve tumor cell or neoplasia killing when used in combination with certain other anti-cancer or chemotherapeutic agents or treatments (e.g. Raben, D. et al. (2002) *Semin. Oncol.* 29:37-46; Herbst, R.S. et al. (2001) *Expert Opin. Biol. Ther.* 1:719-732; Magne, N et al. (2003) *Clin. Can. Res.* 9:4735-4732; Magne, N. et al. (2002)

- British Journal of Cancer 86:819-827; Torrance, C.J. et al. (2000) Nature Med. 6:1024-1028; Gupta, R.A. and DuBois, R.N. (2000) Nature Med. 6:974-975; Tortora, et al. (2003) Clin. Cancer Res. 9:1566-1572; Solomon, B. et al (2003) Int. J. Radiat. Oncol. Biol. Phys. 55:713-723; Krishnan, S. et al. (2003) Frontiers in Bioscience 8, e1-13;
- 5 Huang, S et al. (1999) Cancer Res. 59:1935-1940; Contessa, J. N. et al. (1999) Clin. Cancer Res. 5:405-411; Li, M. et al. Clin. (2002) Cancer Res. 8:3570-3578; Ciardiello, F. et al. (2003) Clin. Cancer Res. 9:1546-1556; Ciardiello, F. et al. (2000) Clin. Cancer Res. 6:3739-3747; Grunwald, V. and Hidalgo, M. (2003) J. Nat. Cancer Inst. 95:851-867; Seymour L. (2003) Current Opin. Investig. Drugs 4(6):658-666; Khalil, M.Y. et al.
- 10 (2003) Expert Rev. Anticancer Ther.3:367-380; Bulgaru, A.M. et al. (2003) Expert Rev. Anticancer Ther.3:269-279; Dancey, J. and Sausville, E.A. (2003) Nature Rev. Drug Discovery 2:92-313; Kim, E.S. et al. (2001) Current Opinion Oncol. 13:506-513; Arteaga, C.L. and Johnson, D.H. (2001) Current Opinion Oncol. 13:491-498; Ciardiello, F. et al. (2000) Clin. Cancer Res. 6:2053-2063; Patent Publication Nos: US
- 15 2003/0108545; US 2002/0076408; and US 2003/0157104; and International Patent Publication Nos: WO 99/60023; WO 01/12227; WO 02/055106; WO 03/088971; WO 01/34574; WO 01/76586; WO 02/05791; and WO 02/089842).

[6] An anti-neoplastic drug would ideally kill cancer cells selectively, with a
20 wide therapeutic index relative to its toxicity towards non-malignant cells. It would also retain its efficacy against malignant cells, even after prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess such an ideal profile. Instead, most possess very narrow therapeutic indexes. Furthermore, cancerous cells exposed to slightly sub-lethal concentrations of a chemotherapeutic agent will very often develop
25 resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents as well.

[7] Thus, there is a need for more efficacious treatment for neoplasia and other proliferative disorders. Strategies for enhancing the therapeutic efficacy of existing drugs
30 have involved changes in the schedule for their administration, and also their use in combination with other anticancer or biochemical modulating agents. Combination therapy is well known as a method that can result in greater efficacy and diminished side effects relative to the use of the therapeutically relevant dose of each agent alone. In some cases, the efficacy of the drug combination is additive (the efficacy of the
35 combination is approximately equal to the sum of the effects of each drug alone), but in

other cases the effect is synergistic (the efficacy of the combination is greater than the sum of the effects of each drug given alone).

[8] However, there remains a critical need for improved treatments for lung and other cancers. This invention provides anti-cancer combination therapies that reduce the dosages for individual components required for efficacy, thereby decreasing side effects associated with each agent, while maintaining or increasing therapeutic value. The invention described herein provides new drug combinations, and methods for using drug combinations in the treatment of lung and other cancers.

SUMMARY OF THE INVENTION

[9] The present invention provides a method for manufacturing a medicament intended for treating tumors or tumors metastases, characterized in that an EGFR kinase inhibitor and gemcitabine are used. Preferably, the combination of a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine is intended for administration to the patient simultaneously or sequentially, with or without additional agents or treatments such as other anti-cancer drugs or radiation therapy.

[10] The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier.

[11] A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

BRIEF DESCRIPTION OF THE FIGURES

[12] **Figure 1: Erlotinib plasma concentrations over time (A) Dose-dependent plasma concentrations (B) Correlation between tumor drug concentrations and plasma drug concentrations.** Tumor-bearing mice were given daily oral doses of erlotinib at 0, 6.3, 12.5, 25.0, 100.0 or 150.0 mg/kg for 21 days. On day 28 post tumor implant, blood (from the retro-orbital sinus) and tumor samples were collected at 1 and 6

hours post dosing. Concentrations of erlotinib were determined using LC-MS/MS.

Values are means \pm SD, n=3.

[13] **Figure 2: Effect of erlotinib on mean tumor volume in H460a NSCLC**

5 **xenograft model.** Mice were implanted with H460a NSCLC cells. When palpable tumors were established, animals were randomized such that each group had a mean starting tumor volume of 100–150 mm³. Mice were given daily oral doses of erlotinib at 0, 6.3, 12.5, 25 or 100 mg/kg for 21 days. Tumor size was measured 3 times per week. Values are means, n=10.

10

[14] **Figure 3: Effect of erlotinib and gemcitabine alone and in combination on mean tumor volume in the H460a NSCLC xenograft model.** Mice were implanted with H460a NSCLC cells. When palpable tumors were established, animals were randomised such that each group had a mean starting tumor volume of 100–150 mm³.

15 Mice were treated for 21 days with vehicle, oral erlotinib alone at 25 or 100 mg/kg/day, i.p. gemcitabine alone at 30 or 120 mg/kg every 3 days, or erlotinib at 25 mg/kg/day with gemcitabine at 30 mg/kg every 3 days. Tumor size was measured 3 times per week. Values are means, n=10.

20 [15] **Figure 4: Effect of erlotinib and gemcitabine alone and in combination on mean tumor volume in the A549 NSCLC xenograft model.** Mice were implanted with A549 NSCLC cells. When palpable tumors were established, animals were randomised such that each group had a mean starting tumor volume of 100–150 mm³.

25 Mice were treated for 21 days with vehicle, oral erlotinib alone at 25 or 100 mg/kg/day, i.p. gemcitabine alone at 30 or 120 mg/kg every 3 days, or erlotinib at 25 mg/kg/day with gemcitabine at 30 mg/kg every 3 days. Tumor size was measured 3 times per week. Values are means, n=10.

[16] **Figure 5: Skin lesions in mice administered erlotinib.** At necropsy, skin

30 samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 5 μ and stained with haematoxylin and eosin. In mice given erlotinib at 100 mg/kg/day for 21 days, skin lesions were grossly characterised as reddened and flaky. Histologically the lesions consisted of diffuse, mild to moderate epidermal acanthosis, epidermal hyperkeratosis, focal escharosis, and infiltration of mostly acute inflammatory cells in the
35 dermis. The lesions were transient and dissipated with continued treatment.

[17] **Figure 6: Photomicrographs of immunohistochemical staining of NSCLC in xenograft models.** Sections of tumors from nude mice were stained for the antigen Ki67 to detect cell proliferation in control mice (A) and mice treated with
5 erlotinib at 100 mg/kg/day for 21 days (B). Dark areas represent Ki67 staining indicative of proliferative activity.

BRIEF DESCRIPTION OF THE TABLES

10

[18] **Table 1: Single-dose pharmacokinetics of erlotinib 20 and 100mg/kg in non-tumour bearing female nu/nu athymic mice.**

[19] **Table 2: Maximum tolerated dose assessment in non-tumour bearing
15 athymic nude mice treated for 14 days (n=5).**

DETAILED DESCRIPTION OF THE INVENTION

20 [20] The term "cancer" in an animal refers to the presence of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Often, cancer cells will be in the form of a tumor, but such cells may exist alone within an animal, or may circulate in the blood stream as
25 independent cells, such as leukemic cells.

[21] "Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that
30 proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (4) any tumors that proliferate by receptor tyrosine kinases; (5) any tumors that proliferate by aberrant serine/threonine kinase activation; and (6) benign and malignant cells of other proliferative diseases in which
35 aberrant serine/threonine kinase activation occurs.

[22] The term "treating" as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing, either partially or completely, the growth of tumors, tumor metastases, or other cancer-causing or neoplastic cells in a patient. The term "treatment" as used herein, unless otherwise
5 indicated, refers to the act of treating.

[23] The phrase "a method of treating" or its equivalent, when applied to, for example, cancer refers to a procedure or course of action that is designed to reduce or eliminate the number of cancer cells in an animal, or to alleviate the symptoms of a
10 cancer. "A method of treating" cancer or another proliferative disorder does not necessarily mean that the cancer cells or other disorder will, in fact, be eliminated, that the number of cells or disorder will, in fact, be reduced, or that the symptoms of a cancer or other disorder will, in fact, be alleviated. Often, a method of treating cancer will be performed even with a low likelihood of success, but which, given the medical history
15 and estimated survival expectancy of an animal, is nevertheless deemed an overall beneficial course of action.

[24] The term "therapeutically effective agent" means a composition that will elicit the biological or medical response of a tissue, system, animal or human that is
20 being sought by the researcher, veterinarian, medical doctor or other clinician.

[25] The term "method for manufacturing a medicament" relates to the manufacturing of a medicament for use in the indication as specified herein and in particular for use in tumors, tumor metastases, or cancer in general. The term relates to
25 the so-called "Swiss-type" claim format in the indication specified.

[26] The term "therapeutically effective amount" or "effective amount" means the amount of the subject compound or combination that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher,
30 veterinarian, medical doctor or other clinician.

[27] The data presented in the Examples herein below demonstrate that co-administration of gemcitabine with an EGFR kinase inhibitor is effective for treatment of advanced cancers, such as colorectal cancer. Accordingly, the present invention provides
35 a method for manufacturing a medicament intended for treating tumors or tumor

[28] metastases in a patient, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used. Preferably, such combination is intended for administration to the patient simultaneously or sequentially. In one embodiment the tumors or tumor metastases to be treated are
5 colorectal tumors or tumor metastases..

[29] Preferably, such substances are intended for administration to the patient simultaneously or sequentially. Therefore, the present invention further provides a method for manufacturing a medicament for treating tumors or tumor metastases,
10 characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially. Preferably, in addition, one or more other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds that enhance the effects of such agents are used..

15

[30] In the context of this invention, additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds that enhance the effects of such agents, include, for example: alkylating agents or agents with an alkylating action, such as cyclophosphamide (CTX; e.g. cytoxan®), chlorambucil (CHL; e.g. leukeran®), cisplatin
20 (CisP; e.g. platinol®) busulfan (e.g. myleran®), melphalan, carmustine (BCNU), streptozotocin, triethylenemelamine (TEM), mitomycin C, and the like; anti-metabolites, such as methotrexate (MTX), etoposide (VP16; e.g. vepesid®), 6-mercaptopurine (6MP), 6-thioguanine (6TG), cytarabine (Ara-C), 5-fluorouracil (5-FU), capecitabine (e.g. Xeloda®), dacarbazine (DTIC), and the like; antibiotics, such as actinomycin D,
25 doxorubicin (DXR; e.g. adriamycin®), daunorubicin (daunomycin), bleomycin, mithramycin and the like; alkaloids, such as vinca alkaloids such as vincristine (VCR), vinblastine, and the like; and other antitumor agents, such as paclitaxel (e.g. taxol®) and pactitaxel derivatives, the cytostatic agents, glucocorticoids such as dexamethasone (DEX; e.g. decadron®) and corticosteroids such as prednisone, nucleoside enzyme
30 inhibitors such as hydroxyurea, amino acid depleting enzymes such as asparaginase, leucovorin, folinic acid and other folic acid derivatives, and similar, diverse antitumor agents. The following agents may also be used as additional agents: arnifostine (e.g. ethyol®), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, lornustine (CCNU), doxorubicin lipo (e.g. doxil®), daunorubicin lipo
35 (e.g. daunoxome®), procarbazine, mitomycin, docetaxel (e.g. taxotere®), aldesleukin,

carboplatin, cladribine, camptothecin, CPT 11 (irinotecan), 10-hydroxy 7-ethyl-camptothecin (SN38), floxuridine, fludarabine, ifosfamide, idarubicin, mesna, interferon alpha, interferon beta, mitoxantrone, topotecan, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman,
 5 plicamycin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil.

[31] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an
 10 EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially, wherein in addition, one or more anti-hormonal agents are used. As used herein, the term "anti-hormonal agent" includes natural or synthetic organic or peptidic compounds that act to regulate or inhibit hormone action on tumors.

15

[32] Antihormonal agents include, for example: steroid receptor antagonists, anti-estrogens such as tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, other aromatase inhibitors, 42-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (e.g. Fareston®); anti-androgens such as flutamide,
 20 nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above; agonists and/or antagonists of glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH) and LHRH (leuteinizing hormone-releasing hormone); the LHRH agonist goserelin acetate, commercially available as Zoladex®
 25 (AstraZeneca); the LHRH antagonist D-alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-proline (e.g. Antide®, Ares-Serono); the LHRH antagonist ganirelix acetate; the steroidal anti-androgens cyproterone acetate (CPA) and megestrol
 30 acetate, commercially available as Megace® (Bristol-Myers Oncology); the nonsteroidal anti-androgen flutamide (2-methyl-N-[4, 20-nitro-3-(trifluoromethyl) phenylpropanamide), commercially available as Eulexin® (Schering Corp.); the non-steroidal anti-androgen nilutamide, (5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)-4'-nitrophenyl]-4,4-dimethyl-imidazolidine-dione); and antagonists for other non-
 35 permissive receptors, such as antagonists for RAR, RXR, TR, VDR, and the like.

[33] The use of the cytotoxic and other anticancer agents described above in chemotherapeutic regimens is generally well characterized in the cancer therapy arts, and their use herein falls under the same considerations for monitoring tolerance and effectiveness and for controlling administration routes and dosages, with some
5 adjustments. For example, the actual dosages of the cytotoxic agents may vary depending upon the patient's cultured cell response determined by using histoculture methods. Generally, the dosage will be reduced compared to the amount used in the absence of additional other agents.

10 [34] Typical dosages of an effective cytotoxic agent can be in the ranges recommended by the manufacturer, and where indicated by in vitro responses or responses in animal models, can be reduced by up to about one order of magnitude concentration or amount. Thus, the actual dosage will depend upon the judgment of the physician, the condition of the patient, and the effectiveness of the therapeutic method
15 based on the in vitro responsiveness of the primary cultured malignant cells or histocultured tissue sample, or the responses observed in the appropriate animal models.

[35] In the context of this invention, of the above additional other cytotoxic, chemotherapeutic or anticancer agents the compounds cisplatin and carboplatin are
20 preferred.

[36] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for
25 administration to the patient simultaneously or sequentially, wherein in addition, one or more angiogenesis inhibitors are used.

[37] Anti-angiogenic agents include, for example: VEGFR inhibitors, such as SU-5416 and SU-6668 (Sugen Inc. of South San Francisco, Calif., USA), or as described in,
30 for example International Application Nos. WO 99/24440, WO 99/62890, WO 95/21613, WO 99/61422, WO 98/50356, WO 99/10349, WO 97/32856, WO 97/22596, WO 98/54093, WO 98/02438, WO 99/16755, and WO 98/02437, and U.S. Patent Nos. 5,883,113, 5,886,020, 5,792,783, 5,834,504 and 6,235,764; VEGF inhibitors such as IM862 (Cytran Inc. of Kirkland, Wash., USA); angiozyme, a synthetic ribozyme from
35 Ribozyme (Boulder, Colo.); and antibodies to VEGF, such as bevacizumab

(e.g. Avastin™, Genentech, South San Francisco, CA), a recombinant humanized antibody to VEGF; integrin receptor antagonists and integrin antagonists, such as to $\alpha_v\beta_3$, $\alpha_v\beta_5$ and $\alpha_v\beta_6$ integrins, and subtypes thereof, e.g. cilengitide (EMD 121974), or the anti-integrin antibodies, such as for example $\alpha_v\beta_3$ specific humanized antibodies (e.g. Vitaxin®); factors such as IFN-alpha (U.S. Patent Nos. 41530,901, 4,503,035, and 5,231,176); angiostatin and plasminogen fragments (e.g. kringle 1-4, kringle 5, kringle 1-3 (O'Reilly, M. S. et al. (1994) Cell 79:315-328; Cao et al. (1996) J. Biol. Chem. 271: 29461-29467; Cao et al. (1997) J. Biol. Chem. 272:22924-22928); endostatin (O'Reilly, M. S. et al. (1997) Cell 88:277; and International Patent Publication No. WO 97/15666); thrombospondin (TSP-1; Frazier, (1991) Curr. Opin. Cell Biol. 3:792); platelet factor 4 (PF4); plasminogen activator/urokinase inhibitors; urokinase receptor antagonists; heparinases; fumagillin analogs such as TNP-4701; suramin and suramin analogs; angiostatic steroids; bFGF antagonists; flk-1 and flt-1 antagonists; anti-angiogenesis agents such as MMP-2 (matrix-metalloproteinase 2) inhibitors and MMP-9 (matrix-metalloproteinase 9) inhibitors. Examples of useful matrix metalloproteinase inhibitors are described in International Patent Publication Nos. WO 96/33172, WO 96/27583, WO 98/07697, WO 98/03516, WO 98/34918, WO 98/34915, WO 98/33768, WO 98/30566, WO 90/05719, WO 99/52910, WO 99/52889, WO 99/29667, and WO 99/07675, European Patent Publication Nos. 818,442, 780,386, 1,004,578, 606,046, and 931,788; Great Britain Patent Publication No. 9912961, and U.S. patent Nos. 5,863,949 and 5,861,510. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).

[38] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially, wherein in addition, one or more tumor cell pro-apoptotic or apoptosis-stimulating agents are used.

[39] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for

administration to the patient simultaneously or sequentially, wherein in addition, one or more signal transduction inhibitors are used..

[40] Signal transduction inhibitors include, for example: erbB2 receptor inhibitors, such as organic molecules, or antibodies that bind to the erbB2 receptor, for example, trastuzumab (e.g. Herceptin®); inhibitors of other protein tyrosine-kinases, e.g. imitinib (e.g. Gleevec®); ras inhibitors; raf inhibitors; MEK inhibitors; mTOR inhibitors; cyclin dependent kinase inhibitors; protein kinase C inhibitors; and PDK-1 inhibitors (see Dancey, J. and Sausville, E.A. (2003) Nature Rev. Drug Discovery 2:92-313, for a description of several examples of such inhibitors, and their use in clinical trials for the treatment of cancer).

[41] ErbB2 receptor inhibitors include, for example: ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome plc), monoclonal antibodies such as AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Tex., USA), and erbB2 inhibitors such as those described in International Publication Nos. WO 98/02434, WO 99/35146, WO 99/35132, WO 98/02437, WO 97/13760, and WO 95/19970, and U.S. Patent Nos. 5,587,458, 5,877,305, 6,465,449 and 6,541,481.

[42] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially, wherein in addition, an anti-HER2 antibody or an immunotherapeutically active fragment thereof is used.

[43] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially, wherein in addition, one or more additional anti-proliferative agents are used.

[44] Additional antiproliferative agents include, for example: Inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFR, including the compounds disclosed and claimed in U.S. patent Nos. 6,080,769, 6,194,438, 6,258,824, 6,586,447, 6,071,935, 6,495,564, 6,150,377, 6,596,735 and

6,479,513, and International Patent Publication WO 01/40217.

[45] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially, wherein in addition, a COX II (cyclooxygenase II) inhibitor is used. Examples of useful COX-II inhibitors include alecoxib (e.g. CelebrexTM), valdecoxib, and rofecoxib.

10 [46] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially, wherein in addition, a radiopharmaceutical is used. Instead of adding a radiopharmaceutical or additionally, treatment with radiation may be carried out.

[47] The source of radiation can be either external or internal to the patient being treated. When the source is external to the patient, the therapy is known as external beam radiation therapy (EBRT). When the source of radiation is internal to the patient, the treatment is called brachytherapy (BT). Radioactive atoms for use in the context of this invention can be selected from the group including, but not limited to, radium, cesium-137, iridium-192, americium-241, gold-198, cobalt-57, copper-67, technetium-99, iodine-123, iodine-131, and indium-111. Where the EGFR kinase inhibitor according to this invention is an antibody, it is also possible to label the antibody with such radioactive isotopes.

[48] Radiation therapy is a standard treatment for controlling unresectable or inoperable tumors and/or tumor metastases. Improved results have been seen when radiation therapy has been combined with chemotherapy. Radiation therapy is based on the principle that high-dose radiation delivered to a target area will result in the death of reproductive cells in both tumor and normal tissues. The radiation dosage regimen is generally defined in terms of radiation absorbed dose (Gy), time and fractionation, and must be carefully defined by the oncologist. The amount of radiation a patient receives will depend on various considerations, but the two most important are the location of the tumor in relation to other critical structures or organs of the body, and the extent to which

the tumor has spread. A typical course of treatment for a patient undergoing radiation therapy will be a treatment schedule over a 1 to 6 week period, with a total dose of between 10 and 80 Gy administered to the patient in a single daily fraction of about 1.8 to 2.0 Gy, 5 days a week. In a preferred embodiment of this invention there is synergy
5 when tumors in human patients are treated with the combination treatment of the invention and radiation. In other words, the inhibition of tumor growth by means of the agents comprising the combination of the invention is enhanced when combined with radiation, optionally with additional chemotherapeutic or anticancer agents. Parameters of adjuvant radiation therapies are, for example, contained in International Patent
10 Publication WO 99/60023.

[49] Also more preferred is a method for manufacturing a medicament for treating tumors or tumor metastases, characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for
15 administration to the patient simultaneously or sequentially, wherein in addition, one or more agents capable of enhancing antitumor immune responses are used.

[50] Agents capable of enhancing antitumor immune responses include, for example: CTLA4 (cytotoxic lymphocyte antigen 4) antibodies (e.g. MDX-CTLA4), and
20 other agents capable of blocking CTLA4. Specific CTLA4 antibodies that can be used in the present invention include those described in U.S. Patent No. 6,682,736.

[51] Also more preferred is a method for manufacturing a medicament for reducing the side effects caused by the treatment of tumors or tumor metastases,
25 characterized in that a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination is used and is intended for administration to the patient simultaneously or sequentially in amounts that are effective to produce an additive, or a superadditive or synergistic antitumor effect, and that are effective at inhibiting the growth of the tumor.

30

[52] The present invention further provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) an effective first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof; and
(ii) an effective second amount of gemcitabine.

35

[53] The present invention also provides a method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) a sub-therapeutic first amount of the EGFR kinase inhibitor erlotinib, or a pharmaceutically acceptable salt thereof; and (ii) a sub-therapeutic second amount of gemcitabine.

5

[54] Additionally, the present invention provides a pharmaceutical composition comprising an EGFR inhibitor and gemcitabine in a pharmaceutically acceptable carrier.

[55] The present invention further provides a pharmaceutical composition, in particular for use in cancer, comprising (i) an effective first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof; and (ii) an effective second amount of gemcitabine. Such composition optionally comprises pharmaceutically acceptable carriers and / or excipients.

[56] The present invention further provides a pharmaceutical composition, in particular for use in cancer, comprising (i) a sub-therapeutic first amount of the EGFR kinase inhibitor erlotinib, or a pharmaceutically acceptable salt thereof; and (ii) a sub-therapeutic second amount of gemcitabine. Such composition optionally comprises pharmaceutically acceptable carriers and / or excipients.

20

[57] Preferably, the EGFR kinase inhibitor is erlotinib.

[58] As used herein, the term "patient" preferably refers to a human in need of treatment with an EGFR kinase inhibitor for any purpose, and more preferably a human in need of such a treatment to treat cancer, or a precancerous condition or lesion. However, the term "patient" can also refer to non-human animals, preferably mammals such as dogs, cats, horses, cows, pigs, sheep and non-human primates, among others, that are in need of treatment with an EGFR kinase inhibitor.

[59] In a preferred embodiment, the patient is a human in need of treatment for cancer, or a precancerous condition or lesion. The cancer is preferably any cancer treatable, either partially or completely, by administration of an EGFR kinase inhibitor. The cancer may be, for example, lung cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer,

35

rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the
5 endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, chronic or acute leukemia, lymphocytic lymphomas, neoplasms of the central
10 nervous system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwannomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers. The precancerous condition or lesion includes, for example, the group consisting of oral leukoplakia,
15 actinic keratosis (solar keratosis), precancerous polyps of the colon or rectum, gastric epithelial dysplasia, adenomatous dysplasia, hereditary nonpolyposis colon cancer syndrome (HNPCC), Barrett's esophagus, bladder dysplasia, and precancerous cervical conditions. Preferably, the cancer is colon cancer and most preferably colorectal cancer. Also preferably, the cancer is lung cancer and most preferably non-small cell lung cancer
20 (NSCL).

[60] For purposes of the present invention, "co-administration of" and "co-administering" gemcitabine with an EGFR kinase inhibitor (both components referred to hereinafter as the "two active agents") refer to any administration of the two active
25 agents, either separately or together, where the two active agents are administered as part of an appropriate dose regimen designed to obtain the benefit of the combination therapy. Thus, the two active agents can be administered either as part of the same pharmaceutical composition or in separate pharmaceutical compositions. Gemcitabine can be administered prior to, at the same time as, or subsequent to administration of the EGFR
30 kinase inhibitor, or in some combination thereof. Where the EGFR kinase inhibitor is administered to the patient at repeated intervals, e.g., during a standard course of treatment, gemcitabine can be administered prior to, at the same time as, or subsequent to, each administration of the EGFR kinase inhibitor, or some combination thereof, or at different intervals in relation to the EGFR kinase inhibitor treatment, or in a single dose
35 prior to, at any time during, or subsequent to the course of treatment with the EGFR

kinase inhibitor.

[61] The EGFR kinase inhibitor will typically be administered to the patient in a dose regimen that provides for the most effective treatment of the cancer (from both efficacy and safety perspectives) for which the patient is being treated, as known in the art, and as disclosed, e.g. in International Patent Publication No. WO 01/34574. In conducting the treatment method of the present invention, the EGFR kinase inhibitor can be administered in any effective manner known in the art, such as by oral, topical, intravenous, intra-peritoneal, intramuscular, intra-articular, subcutaneous, intranasal, intra-ocular, vaginal, rectal, or intradermal routes, depending upon the type of cancer being treated, the type of EGFR kinase inhibitor being used (e.g., small molecule, antibody, RNAi or antisense construct), and the medical judgement of the prescribing physician as based, e.g., on the results of published clinical studies.

[62] The amount of EGFR kinase inhibitor administered and the timing of EGFR kinase inhibitor administration will depend on the type (species, gender, age, weight, etc.) and condition of the patient being treated, the severity of the disease or condition being treated, and on the route of administration. For example, small molecule EGFR kinase inhibitors can be administered to a patient in doses ranging from 0.001 to 100 mg/kg of body weight per day or per week in single or divided doses, or by continuous infusion (see for example, International Patent Publication No. WO 01/34574). In particular, erlotinib HCl can be administered to a patient in doses ranging from 5-200 mg per day, or 100-1600 mg per week, in single or divided doses, or by continuous infusion. A preferred dose is 150 mg/day. Antibody-based EGFR kinase inhibitors, or antisense, RNAi or ribozyme constructs, can be administered to a patient in doses ranging from 0.1 to 100 mg/kg of body weight per day or per week in single or divided doses, or by continuous infusion. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

[63] The EGFR kinase inhibitors and gemcitabine can be administered either separately or together by the same or different routes, and in a wide variety of different dosage forms. For example, the EGFR kinase inhibitor is preferably administered orally or parenterally, whereas gemcitabine is preferably administered parenterally. Where the

EGFR kinase inhibitor is erlotinib HCl (Tarceva™), oral administration is preferable.

[64] The EGFR kinase inhibitor can be administered with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Administration of such dosage forms can be carried out in single or multiple doses. Carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Oral pharmaceutical compositions can be suitably sweetened and/or flavored.

[65] The EGFR kinase inhibitor and gemcitabine can be combined together with various pharmaceutically acceptable inert carriers in the form of sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, and the like. Administration of such dosage forms can be carried out in single or multiple doses. Carriers include solid diluents or fillers, sterile aqueous media, and various non-toxic organic solvents, etc.

[66] All formulations comprising proteinaceous EGFR kinase inhibitors should be selected so as to avoid denaturation and/or degradation and loss of biological activity of the inhibitor.

[67] Methods of preparing pharmaceutical compositions comprising an EGFR kinase inhibitor are known in the art, and are described, e.g. in International Patent Publication No. WO 01/34574. Methods of preparing pharmaceutical compositions comprising gemcitabine are also well known in the art. In view of the teaching of the present invention, methods of preparing pharmaceutical compositions comprising both an EGFR kinase inhibitor and gemcitabine will be apparent from the above-cited publications and from other known references, such as Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 18th edition (1990).

[68] For oral administration of EGFR kinase inhibitors, tablets containing one or both of the active agents are combined with any of various excipients such as, for example, micro-crystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine, along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinyl pyrrolidone, sucrose, gelatin and acacia. Additionally,

lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the EGFR kinase inhibitor may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

[69] For parenteral administration of either or both of the active agents, solutions in either sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions comprising the active agent or a corresponding water-soluble salt thereof. Such sterile aqueous solutions are preferably suitably buffered, and are also preferably rendered isotonic, e.g., with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. The oily solutions are suitable for intra-articular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. Any parenteral formulation selected for administration of proteinaceous EGFR kinase inhibitors should be selected so as to avoid denaturation and loss of biological activity of the inhibitor.

[70] Additionally, it is possible to topically administer either or both of the active agents, by way of, for example, creams, lotions, jellies, gels, pastes, ointments, salves and the like, in accordance with standard pharmaceutical practice. For example, a topical formulation comprising either an EGFR kinase inhibitor or gemcitabine in about 0.1% (w/v) to about 5% (w/v) concentration can be prepared.

[71] For veterinary purposes, the active agents can be administered separately or together to animals using any of the forms and by any of the routes described above. In a preferred embodiment, the EGFR kinase inhibitor is administered in the form of a capsule, bolus, tablet, liquid drench, by injection or as an implant. As an alternative, the EGFR kinase inhibitor can be administered with the animal feedstuff, and for this purpose a concentrated feed additive or premix may be prepared for a normal animal

feed. The gemcitabine is preferably administered in the form of liquid drench, by injection or as an implant. Such formulations are prepared in a conventional manner in accordance with standard veterinary practice.

5 [72] The present invention further provides a kit comprising a single container comprising both an EGFR kinase inhibitor and gemcitabine. The present invention further provides a kit comprising a first container comprising an EGFR kinase inhibitor and a second container comprising gemcitabine. In a preferred embodiment, the kit
10 containers may further include a pharmaceutically acceptable carrier. The kit may further include a sterile diluent, which is preferably stored in a separate additional container. The kit may further include a package insert comprising printed instructions directing the use of the combined treatment as a method for treating cancer.

[73] As used herein, the term "EGFR kinase inhibitor" refers to any EGFR kinase
15 inhibitor that is currently known in the art or that will be identified in the future, and includes any chemical entity that, upon administration to a patient, results in inhibition of a biological activity associated with activation of the EGF receptor in the patient, including any of the downstream biological effects otherwise resulting from the binding
20 to EGFR of its natural ligand. Such EGFR kinase inhibitors include any agent that can block EGFR activation or any of the downstream biological effects of EGFR activation that are relevant to treating cancer in a patient. Such an inhibitor can act by binding directly to the intracellular domain of the receptor and inhibiting its kinase activity. Alternatively, such an inhibitor can act by occupying the ligand binding site or a portion
25 thereof of the EGFR receptor, thereby making the receptor inaccessible to its natural ligand so that its normal biological activity is prevented or reduced. Alternatively, such an inhibitor can act by modulating the dimerization of EGFR polypeptides, or interaction of EGFR polypeptide with other proteins, or enhance ubiquitination and endocytotic degradation of EGFR. EGFR kinase inhibitors include but are not limited to low
30 molecular weight inhibitors, antibodies or antibody fragments, antisense constructs, small inhibitory RNAs (i.e. RNA interference by dsRNA; RNAi), and ribozymes. In a preferred embodiment, the EGFR kinase inhibitor is a small organic molecule or an antibody that binds specifically to the human EGFR.

[74] EGFR kinase inhibitors that include, for example quinazoline EGFR kinase
35 inhibitors, pyrido-pyrimidine EGFR kinase inhibitors, pyrimido-pyrimidine EGFR kinase

inhibitors, pyrrolo-pyrimidine EGFR kinase inhibitors, pyrazolo-pyrimidine EGFR kinase inhibitors, phenylamino-pyrimidine EGFR kinase inhibitors, oxindole EGFR kinase inhibitors, indolocarbazole EGFR kinase inhibitors, phthalazine EGFR kinase inhibitors, isoflavone EGFR kinase inhibitors, quinalone EGFR kinase inhibitors, and tyrphostin EGFR kinase inhibitors, such as those described in the following patent publications, and all pharmaceutically acceptable salts and solvates of said EGFR kinase inhibitors: International Patent Publication Nos. WO 96/33980, WO 96/30347, WO 97/30034, WO 97/30044, WO 97/38994, WO 97/49688, WO 98/02434, WO 97/38983, WO 95/19774, WO 95/19970, WO 97/13771, WO 98/02437, WO 98/02438, WO 97/32881, WO 98/33798, WO 97/32880, WO 97/3288, WO 97/02266, WO 97/27199, WO 98/07726, WO 97/34895, WO 96/31510, WO 98/14449, WO 98/14450, WO 98/14451, WO 95/09847, WO 97/19065, WO 98/17662, WO 99/35146, WO 99/35132, WO 99/07701, and WO 92/20642; European Patent Application Nos. EP 520722, EP 566226, EP 787772, EP 837063, and EP 682027; U.S. Patent Nos. 5,747,498, 5,789,427, 5,650,415, and 5,656,643; and German Patent Application No. DE 19629652. Additional non-limiting examples of low molecular weight EGFR kinase inhibitors include any of the EGFR kinase inhibitors described in Traxler, P., 1998, Exp. Opin. Ther. Patents 8(12):1599-1625.

[75] Specific preferred examples of low molecular weight EGFR kinase inhibitors that can be used according to the present invention include [6,7-bis(2-methoxyethoxy)-4-quinazolin-4-yl]-(3-ethynylphenyl) amine (also known as OSI-774, erlotinib, or Tarceva™ (erlotinib HCl); OSI Pharmaceuticals/Genentech/Roche) (U.S. Pat. No. 5,747,498; International Patent Publication No. WO 01/34574, and Moyer, J.D. et al. (1997) Cancer Res. 57:4838-4848); CI-1033 (formerly known as PD183805; Pfizer) (Sherwood et al., 1999, Proc. Am. Assoc. Cancer Res. 40:723); PD-158780 (Pfizer); AG-1478 (University of California); CGP-59326 (Novartis); PKI-166 (Novartis); EKB-569 (Wyeth); GW-2016 (also known as GW-572016 or lapatinib ditosylate ; GSK); and gefitinib (also known as ZD1839 or Iressa™; Astrazeneca) (Woodburn et al., 1997, Proc. Am. Assoc. Cancer Res. 38:633). A particularly preferred low molecular weight EGFR kinase inhibitor that can be used according to the present invention is [6,7-bis(2-methoxyethoxy)-4-quinazolin-4-yl]-(3-ethynylphenyl) amine (i.e. erlotinib), its hydrochloride salt (i.e. erlotinib HCl, Tarceva™), or other salt forms (e.g. erlotinib mesylate).

[76] Antibody-based EGFR kinase inhibitors include any anti-EGFR antibody or antibody fragment that can partially or completely block EGFR activation by its natural ligand. Non-limiting examples of antibody-based EGFR kinase inhibitors include those described in Modjtahedi, H., et al., 1993, Br. J. Cancer 67:247-253; Teramoto, T., et al., 5 1996, Cancer 77:639-645; Goldstein et al., 1995, Clin. Cancer Res. 1:1311-1318; Huang, S. M., et al., 1999, Cancer Res. 15:59(8):1935-40; and Yang, X., et al., 1999, Cancer Res. 59:1236-1243. Thus, the EGFR kinase inhibitor can be monoclonal antibody Mab E7.6.3 (Yang, X.D. et al. (1999) Cancer Res. 59:1236-43), or Mab C225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having the binding specificity 10 thereof. Suitable monoclonal antibody EGFR kinase inhibitors include, but are not limited to, IMC-C225 (also known as cetuximab or Erbitux™; Imclone Systems), ABX-EGF (Abgenix), EMD 72000 (Merck KgaA, Darmstadt), RH3 (York Medical Bioscience Inc.), and MDX-447 (Medarex/ Merck KgaA).

15 [77] Additional antibody-based EGFR kinase inhibitors can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others. Various adjuvants known in the art can be used to enhance antibody production.

20 [78] Although antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred. Monoclonal antibodies against EGFR can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. Techniques for production and isolation include but are not limited to the hybridoma technique originally described by Kohler 25 and Milstein (Nature, 1975, 256: 495-497); the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cote et al., 1983, Proc. Nati. Acad. Sci. USA 80: 2026-2030); and the EBV-hybridoma technique (Cole et al, 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

30 [79] Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Patent No. 4,946,778) can be adapted to produce anti-EGFR single chain antibodies. Antibody-based EGFR kinase inhibitors useful in practicing the present invention also include anti-EGFR antibody fragments including but not limited to F(ab').sub.2 fragments, which can be generated by pepsin digestion of an intact antibody 35 molecule, and Fab fragments, which can be generated by reducing the disulfide bridges

of the F(ab').sub.2 fragments. Alternatively, Fab and/or scFv expression libraries can be constructed (see, e.g., Huse et al., 1989, Science 246: 1275-1281) to allow rapid identification of fragments having the desired specificity to EGFR.

5 [80] Techniques for the production and isolation of monoclonal antibodies and antibody fragments are well-known in the art, and are described in Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, and in J. W. Goding, 1986, Monoclonal Antibodies: Principles and Practice, Academic Press, London. Humanized anti-EGFR antibodies and antibody fragments can also be prepared
10 according to known techniques such as those described in Vaughn, T. J. et al., 1998, Nature Biotech. 16:535-539 and references cited therein, and such antibodies or fragments thereof are also useful in practicing the present invention.

[81] EGFR kinase inhibitors for use in the present invention can alternatively be
15 based on antisense oligonucleotide constructs. Anti-sense oligonucleotides, including anti-sense RNA molecules and anti-sense DNA molecules, would act to directly block the translation of EGFR mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of EGFR kinase protein, and thus activity, in a cell. For example, antisense oligonucleotides of at least
20 about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding EGFR can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion. Methods for using antisense techniques for specifically inhibiting gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Patent Nos. 6,566,135; 6,566,131; 6,365,354;
25 6,410,323; 6,107,091; 6,046,321; and 5,981,732).

[82] Small inhibitory RNAs (siRNAs) can also function as EGFR kinase inhibitors for use in the present invention. EGFR gene expression can be reduced by contacting the tumor, subject or cell with a small double stranded RNA (dsRNA), or a
30 vector or construct causing the production of a small double stranded RNA, such that expression of EGFR is specifically inhibited (i.e. RNA interference or RNAi). Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschl, T., et al. (1999) Genes Dev. 13(24):3191-3197; Elbashir, S.M. et al. (2001) Nature 411:494-498; Hannon, G.J. (2002) Nature 418:244-251; McManus, M.T. and Sharp, P. A. (2002) Nature Reviews Genetics
35

3:737-747; Bremmelkamp, T.R. et al. (2002) Science 296:550-553; U.S. Patent Nos. 6,573,099 and 6,506,559; and International Patent Publication Nos. WO 01/36646, WO 99/32619, and WO 01/68836).

5 [83] Ribozymes can also function as EGFR kinase inhibitors for use in the present invention. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Engineered hammerhead motif ribozyme molecules that
10 specifically and efficiently catalyze endonucleolytic cleavage of EGFR mRNA sequences are thereby useful within the scope of the present invention. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and
15 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.

20

[84] Both antisense oligonucleotides and ribozymes useful as EGFR kinase inhibitors can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramidite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo
25 transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Various modifications to the oligonucleotides of the invention can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of
30 flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.

[85] The invention also encompasses a pharmaceutical composition that is
35 comprised of an EGFR kinase inhibitor and gemcitabine combination in combination

with a pharmaceutically acceptable carrier.

[86] Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of an EGFR kinase inhibitor
5 compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof).

[87] Moreover, within this preferred embodiment, the invention encompasses a pharmaceutical composition for the treatment of disease, the use of which results in the
10 inhibition of growth of neoplastic cells, benign or malignant tumors, or metastases, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of an EGFR kinase inhibitor compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof).

15 [88] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When a compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium,
20 copper (cupric and cuprous), ferric, ferrous, lithium, magnesium, manganese (manganic and manganous), potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally
25 occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine,
30 histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

[89] When a compound of the present invention is basic, its corresponding salt
35 can be conveniently prepared from pharmaceutically acceptable non-toxic acids,

including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.

[90] The pharmaceutical compositions of the present invention comprise an EGFR kinase inhibitor compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof) as active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. Other therapeutic agents may include those cytotoxic, chemotherapeutic or anti-cancer agents, or agents which enhance the effects of such agents, as listed above. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

[91] In practice, the compounds represented by an EGFR kinase inhibitor compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof) of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, an EGFR kinase inhibitor compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof) may also be administered by controlled release means and/or delivery devices. The combination compositions may

be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredients with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid
5 carriers or both. The product can then be conveniently shaped into the desired presentation.

[92] Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and an EGFR kinase inhibitor compound and
10 gemcitabine combination (including pharmaceutically acceptable salts of each component thereof). An EGFR kinase inhibitor compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof), can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds. Other therapeutically active compounds may include
15 those cytotoxic, chemotherapeutic or anti-cancer agents, or agents which enhance the effects of such agents, as listed above.

[93] Thus in one embodiment of this invention, a pharmaceutical composition can comprise an EGFR kinase inhibitor compound and gemcitabine in combination with an
20 anticancer agent, wherein said anti-cancer agent is a member selected from the group consisting of alkylating drugs, antimetabolites, microtubule inhibitors, podophyllotoxins, antibiotics, nitrosoureas, hormone therapies, kinase inhibitors, activators of tumor cell apoptosis, and antiangiogenic agents.

25 [94] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

30 [95] In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as
35 starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants,

binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

[96] A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.

[97] For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material that may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1mg to about 2g of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or 1000mg.

[98] Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

[99] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions

must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol),
5 vegetable oils, and suitable mixtures thereof.

[100] Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in
10 transdermal devices. These formulations may be prepared, utilizing an EGFR kinase inhibitor compound and gemcitabine combination (including pharmaceutically acceptable salts of each component thereof) of this invention, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the
15 compound, to produce a cream or ointment having a desired consistency.

[101] Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials
20 commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.

[102] In addition to the aforementioned carrier ingredients, the pharmaceutical
25 formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing an EGFR kinase inhibitor compound and
30 gemcitabine combination (including pharmaceutically acceptable salts of each component thereof) may also be prepared in powder or liquid concentrate form.

[103] Dosage levels for the compounds of the combination of this invention will be approximately as described herein, or as described in the art for these compounds. It is
35 understood, however, that the specific dose level for any particular patient will depend

upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

5 [104] This invention will be better understood from the Experimental Details that follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter, and are not to be considered in any way limited thereto.

10

[105] **Experimental Details:**

[106] Introduction

15 [107] The cancer cell-specific epidermal growth factor receptor (HER1/EGFR) is a valuable molecular target in cancer therapy (Ciardiello, F and Tortora G. (2002) Expert Opin. Investig. Drugs 11:755–768). Many cancers over-express HER1/EGFR: head and neck squamous cell carcinoma (70–100%), non-small cell lung cancer (NSCLC) (50–90%), prostate cancer (40–70%), glioma (10–50%), gastric cancer (30–60%), breast
20 cancer (35–70%), colorectal cancer (45–80%), pancreatic cancer (30–50%) and ovarian cancer (35–60%) (Ciardiello, F and Tortora G. (2002) Expert Opin. Investig. Drugs 11:755–768); Salomon D.S., et al. (1995) Crit. Rev. Oncol. Hematol. 19:183–232). Salomon et al also highlighted the link between over-expressed HER1/EGFR and patients with advanced disease, metastases and poor prognosis.

25

[108] NSCLC is the most common lung cancer. According to the extent of the disease, the treatment approach will differ. For early stage of the disease, surgery is the only cure, and a multimodal approach with chemo/radio therapy can be associated with improved outcome. In advanced disease, chemotherapy is the main option, which offers
30 small improvements in overall survival. Thus, the medical need remains high in NSCLC with the search for more effective and better tolerated regimens. Many traditional cytotoxics have been used as monotherapy in NSCLC, including vindesine, carboplatin, etoposide, ifosfamide, cyclophosphamide, vincristine, and mitomycin and cisplatin (Rajkumar S.V., and Adjei AA. (1998) Cancer Treat Rev. 24:35–53). Monotherapy with
35 these drugs produces only small improvement, but combination therapy with cisplatin

has lessened patients' illness and improved their quality of life in randomised trials (Bunn P.A. Jr, and Kelly K. (1998) Clin Cancer Res. 4(5):1087–1100).

- [109] Gemcitabine was developed in the 1990s, and inhibits ribonuclease reductase. Gemcitabine monotherapy has a greater probability of tumor response and improved patient quality of life (in terms of reduced hair loss, nausea and vomiting, and appetite loss) than standard cisplatin/etoposide chemotherapy (ten Bokkel W.W., et al. (1999) Lung Cancer 26(2):85–94).
- 10 [110] Combination trials by the European Organization for Research and Treatment of Cancer (EORTC) compared cisplatin and teniposide to cisplatin and paclitaxel (Giaccone G, et al.. (1998) J Clin. Oncol. 16:2133–2141). As the latter combination gave better palliation for advanced NSCLC (even though a clear survival benefit was not met), it has been recommended as one of the standard of care for advanced NSCLC patients. In addition, a combination of gemcitabine and cisplatin has been shown to act synergistically *in vitro* and at least additively *in vivo* (Peters G.J. et al. (1995) Semin. Oncol. 22(4 Suppl. 11):72–79). In phase II trials, the response rate for gemcitabine and cisplatin was 47% and median survival 57 weeks, with a 1-year survival rate of 48% (Bunn P.A. Jr, and Kelly K. (1998) Clin Cancer Res. 4(5):1087–1100).
- 15 20 [111] New treatments for cancer take a cancer-cell specific approach, and promise less toxicity than the older cytotoxic drugs. As cancer cell-specific targets are only part of the disease aetiology, treatments combining targeted and conventional drugs may have a synergistic effect. Optimal treatment of NSCLC is likely to consist of EGFR inhibitors in combination with traditional chemotherapy.
- 25 [112] Erlotinib (TarcevaTM, OSI-774) is a selective, orally available small-molecule inhibitor of the HER1/EGFR tyrosine-kinase domain. It has potent antitumour activity in preclinical animal models of head and neck and vulval carcinoma (Pollack V.A., et al. (1999) J. Pharmacol. Exp. Ther. 291:739–48). Erlotinib induces apoptosis *in vitro* and is active against various EGFR-expressing human tumour xenografts *in vivo* (Moyer J.D. et al. (1997) Cancer Res. 57:4838–4848). In an open-label, phase II study of NSCLC patients who had failed platinum-based chemotherapy (Perez-Soler R. et al. (2001) Proc. Am. Soc. Clin. Oncol. 20:310a (Abstract 1235)), erlotinib had encouraging anticancer activity.
- 30 35

[113] In this study we investigated whether combining erlotinib with cisplatin or gemcitabine in athymic nude mice bearing NSCLC xenograft models acts synergistically or antagonistically in inhibiting tumour growth. The H460a and A549 NSCLC tumour models were chosen because they clearly express EGFR, with around 70,000–80,000 binding sites per cell (Bianco, C. et al. (2002) Clin. Cancer Res. 8(10):3250–3258; Lee, M. et al. (1992) J Natl. Cancer Inst. Monogr. (13):117–123). A549 is slow growing and H460a is more aggressive and faster growing.

[114] **Materials and Methods**

[115] **Animals**

[116] Female, athymic, nu/nu-nuBR nude mice (Charles River Labs, Wilmington, USA) of around 10–12 weeks and weighing 23–25g were used. The health of the mice was assessed daily by observation and analysis of blood samples taken from sentinel animals on the shared shelf racks. All animals were allowed to acclimatise and recover from shipping-related stress for 1 week.

[117] Autoclaved water and irradiated food (5058-ms Pico Lab [mouse] breed chow, Purina Mills, Richmond, IN) were provided *ad libitum*, and the animals were kept in a 12-hour light and dark cycle. Cages, bedding and water bottles were autoclaved before use and changed weekly. All animal experiments were in accordance with protocols approved by the Roche Animal Care and Use Committee.

[118] **Cell culture and animal studies**

[119] H460a cells (provided by Dr Jack Roth, MD, Anderson) were grown in Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% Foetal Bovine Serum (FBS). A549 cells (American Type Culture Collection [Manassas, VA] were grown in Roswell Park Memorial Institute medium (RPMI) 1640 + 10% FBS. The cell concentrations for implant were 1×10^7 cells/0.2mL for H460a and 7.5×10^6 cells/0.2mL for A549.

[120] Cells were suspended in phosphate-buffered saline, and implanted subcutaneously in the right flank of each mouse. Once palpable tumours were

established, animals were randomised so that all groups had similar starting mean tumour volumes of 100–150mm³. Tumour measurements and mouse weights were taken three times per week. Animals were individually monitored throughout the experiment.

5 [121] Test agents and drug treatment.

[122] Erlotinib (OSI Pharmaceuticals, Uniondale, NY) was formulated as a fine suspension with sodium carboxymethylcellulose and Tween 80 in water for injection. Erlotinib (0.2mL/animal) was given orally using a 1mL syringe and 18-gauge gavage
10 needle. All groups were treated daily for 3 weeks.

[123] Lyophilised gemcitabine (GemzarTM, Lilly Research Center Ltd) was formulated in the prepackaged vial with sterile saline according to the label instructions, giving a solution containing 38mg/mL active compound. An aliquot of the stock vial
15 solutions was taken for each dose group, consisting of the drug needed for the entire study, and diluted further with sterile saline, to give a solution of 0.5mL dosing volume for each animal. Gemcitabine was given intraperitoneally (i.p.) using a 3mL syringe and 26-gauge needle. All groups were treated every 3 days for 3 weeks (a total of six injections).

20

[124] Calculations and statistical analysis.

[125] Weight loss was calculated as percent change in mean group body weight, using the formula:

25

[126] $((W-W_0)/W_0) \times 100$

[127] where 'W' represents mean body weight of the treated group at a particular day, and 'W₀' represents mean body weight of the same group at start of treatment.

30 Maximum weight loss was also calculated using the above formula, giving the maximum percentage of body weight lost at any time in the entire experiment for a particular group. Treatment efficacy was assessed by tumor growth inhibition. Tumour volumes of treated groups were given as percentages of tumor volumes of the control groups (%T/C), using the formula:

35

[128] $100 \times ((T - T_0) / (C - C_0))$

[129] where 'T' represents mean tumor volume of a treated group on a specific day during the experiment, 'T₀' represented mean tumor volume of the same group on the first day of treatment, C represents mean tumor volume of a control group on a particular day of the experiment, and C₀ represents mean tumor volume of the same group on the first day of treatment.

[130] Tumor growth inhibition was calculated using the formula:

[131] $100 - \%T/C$

[132] Tumor volume (mm³) was calculated using the ellipsoid formula:

[133] $(D \times (d^2)) / 2$

[134] where 'D' represents the large diameter of the tumor, and 'd' represents the small diameter. In some cases, tumor regression and/or percentage change in tumor volume was calculated using the formula:

[135] $((T - T_0) / T_0) \times 100$

[136] where 'T' represents mean tumor volume of the treated group at a particular day, and 'T₀' represents mean tumor volume of the same treated group at the start of treatment.

[137] Statistical analysis was by the rank sum test and one-way analysis of variance (ANOVA) and a post-hoc Bonferroni t-test (SigmaStat, version 2.03, Jandel Scientific, San Francisco, CA). The significance level was set at $p \leq 0.05$.

[138] Pharmacokinetic analysis

[139] For single-dose pharmacokinetics (PK), blood samples from three mice per time point were collected by cardiac puncture at 5, 15, 30, 60 minutes and 2, 4, 8, 16, 24 hours post-dose. For chronically treated animals, blood samples from two or three mice

per time point were collected via the retro-orbital sinus at 1 and 6 hours. Collection tubes contained ethylene diamine tetra-acetic acid (EDTA) as anticoagulant. Samples were stored at -70°C . Plasma concentrations of erlotinib were determined using a liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with
5 quantification limits of 1ng/mL . PK parameters were estimated by non-compartmental analysis of the composite data, using the PK evaluation programme WinNonlin PRO[®] version 3.1 (Pharsight Inc). In one study, erlotinib tumor (H460a) concentrations were determined using a selective LC-MS/MS method with a quantification limit of 1ng/g tissue.

10

[140] Pathology/necropsy

[141] Five mice per treatment from all remaining groups were given a full necropsy at the end of the study. Whole blood was also collected from these mice for haematology
15 and clinical chemistry.

20

[142] Tumor samples were fixed by immersion in 10% zinc formalin then processed in a Tissue-Tek[®] VIP (Sakura) and embedded in paraffin. Sections for immunohistochemistry were cut at 5μ . Pre-immune rabbit or goat serum (Dako Ltd) was used as the negative control. Sections were immersed in Target Retrieval Solution (Dako Ltd) and heated to 94°C in a steamer (Black & Decker) for 20 minutes. Endogenous peroxidase activity was quenched with 6% H_2O_2 in methanol for 15 minutes.

25

[143] To block non-specific tissue-binding sites, sections were blocked by 10% normal serum from the species in which the secondary antibody was raised. Sections were incubated for 20 minutes at room temperature in serum prepared in Ultra-V (Lab Vision).

30

[144] For platelet endothelial cell adhesion molecule (PECAM-1, CD31) antigen and EGFR antigen, the sections were incubated overnight at room temperature with a polyclonal goat anti-PECAM-1 IgG (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:800 in Antibody Diluent (Dako Ltd) or with a polyclonal rabbit anti-EGFR IgG (BioGenex, San Ramon, CA) diluted 1:50 in Antibody Diluent (Dako Ltd). Sections were incubated with Vectastain Elite ABC-peroxidase (Vector Laboratories) for 45
35 minutes at room temperature.

[145] For the Ki-67 antigen, sections were incubated for 1 hour at room temperature with a polyclonal anti Ki-67 IgG (NeoMarkers, Fremont, CA) diluted 1:2,000 in Antibody Diluent (Dako Ltd), followed by the addition of horseradish peroxidase-labelled streptavidin complex for 30 minutes.

5

[146] To detect apoptosis, the TUNEL TdT-FragEL™ DNA fragmentation detection kit (Oncogene Research Products, San Diego, CA) was used according to the manufacturer's recommendations. For all four antigens, Vector Nova Red (Vector Laboratories) was the final chromogen and haematoxylin the nuclear counterstain.

10

[147] Results and Discussion

[148] Results

15

[149] EGFR immunohistochemical staining in NSCLC xenografts

[150] The EGFR expression pattern in the H460a and A549 tumors was examined by immunohistochemistry. Both cell lines had a similar membranous pattern of staining for EGFR (data not shown). This confirms past results showing equivalent expression of EGFR in these two tumor lines (Bianco, C. et al. (2002) Clin. Cancer Res. 8(10):3250–3258; Lee, M. et al. (1992) J Natl. Cancer Inst. Monogr. (13):117–123).

20

[151] Single and chronic-dose PK assessment of erlotinib in athymic nude mice

25

[152] In non-tumor bearing mice.

[153] Erlotinib 20 and 100mg/kg was given by gavage to female nu/nu athymic mice. The doses refer to the hydrochloride salt with an active drug (free base) content of 91.5%. The formulations were sodium carboxymethylcellulose suspensions containing 2.5mg/mL and 12.5mg/mL of erlotinib, respectively. Three animals per time point were evaluated for PK data (Figure 4).

30

[154] The mice given 100mg/kg had high systemic exposures to erlotinib, with an AUC_{last} value of approximately 196,000 h*ng/mL. The AUC_{last} following 20mg/kg was 33,500 h*ng/mL. The exposure (AUC) was dose-proportional. Mean maximum plasma

35

concentrations were approximately 24,000ng/mL after 100mg/kg, and 9,100ng/mL after 20mg/kg. Maximum plasma concentration was 0.5–1.0 hours post dose. Mean apparent terminal half-life was about 4 hours and the average mean residence time about 7 hours.

5 [155] In tumor-bearing mice.

[156] After erlotinib 6.3, 12.5, 25.0, 100.0, and 150.0mg/kg was given orally to nu/nu athymic mice, plasma concentration was up to 16,700ng/mL and 8,870ng/mL at 1 hour and 6 hours post dose, respectively (Figure 1a). The respective mean tumor
10 concentrations following oral doses of 150mg/kg, sampled at the same time points as the plasma samples, were 4,800 and 3,090ng/g tissue.

[157] Inter-individual variability of the plasma concentrations was moderate, with a relative standard deviation (RSD) of about 35–40% (range: 5.2–120%). The exposure
15 was dose-dependent and more than dose-proportional with ascending doses. Tumor concentrations also correlated well with plasma concentrations in this study (Figure 1b).

[158] Determination of maximum tolerated doses (MTD) in athymic nude mice.

20 [159] Erlotinib MTD

[160] The MTD for erlotinib was 100mg/kg (Figure 6). Mice showing signs of toxicity all had similar lesions. Gross toxicity was found in the skin and gastro-intestinal tract. One mouse in the 400mg/kg group died. The rest of the animals in this group were
25 euthanized because of morbidity. Mice given 200mg/kg had marked weight loss and all were euthanized. Our previous efficacy studies have shown, however, that erlotinib 150mg/kg in this formulation is also well tolerated for 3 weeks (authors, unpublished observation).

30 [161] Gemcitabine MTD

[162] In a 2-week MTD study in nude mice given gemcitabine, there were no signs of overt toxicity (weight loss or gross clinical signs) in any of the treated groups. Gemcitabine's main toxicity is myelosuppression (Hoang, T. et al. (2003) Lung Cancer
35 42(1):97–102; Philip PA. (2002) Cancer 95(4 Suppl):908–911; Tripathy, D. (2002) Clin.

Breast Cancer 3 (Suppl 1):8-11). Since terminal blood samples for complete blood counts were not taken, it is not known if there was myelosuppression in any of the dose groups.

[163] Based on these findings and data found in the literature (Rajkumar S.V., and
5 Adjei AA. (1998) Cancer Treat Rev. 24:35-53; Bunn P.A. Jr, and Kelly K. (1998) Clin
Cancer Res. 4(5):1087-1100; ten Bokkel W.W., et al. (1999) Lung Cancer 26(2):85-94),
we decided to use a dose of 120mg/kg every 3 days in later efficacy studies as the
maximum dose. We were being cautious in using higher doses as different sensitivities
have been shown for tumor-bearing animals, and the level of toleration can even be
10 tumor-line-specific (Merriman, R.L. et al. (1996) Invest. New Drugs 14(3):243-247).

[164] Effects of erlotinib on established NSCLC xenografts.

[165] Dose response study in H460a.

15

[166] At the end of the study in the H460a NSCLC xenograft (day 28 post tumor
implantation), erlotinib, as a monotherapy, had significant dose-dependent efficacy. In
the 100mg/kg group there was growth inhibition of 61% ($p \leq 0.001$ versus vehicle
control).

20

[167] The other groups had the following growth inhibition: 25mg/kg: 46%
($p \leq 0.001$ versus vehicle control); 12.5mg/kg: 36% ($p = 0.003$ versus vehicle control);
6.25mg/kg: 28% ($p = 0.014$ versus vehicle control) (Figure 2). There were no partial or
complete regressions.

25

[168] Combination activity of erlotinib and gemcitabine in H460a.

[169] At the 28-day endpoint, erlotinib 100mg/kg had significantly inhibited tumor
growth by 71% ($p = 0.002$) (Figure 3). Erlotinib 25mg/kg had a suboptimal efficacy of
30 30%.

[170] Gemcitabine monotherapy was tested at the MTD of 120mg/kg every 3 days,
and at a quarter of the MTD, 30mg/kg, every 3 days. Gemcitabine 120mg/kg every 3
days significantly inhibited tumor growth (93%, $p \leq 0.001$). At the fraction of the MTD,
35 tumor growth inhibition was 64% ($p \leq 0.001$).

[171] The combination of gemcitabine 120mg/kg every 3 days and erlotinib oral 100mg/kg was lethal, with signs of toxicity at day 5 post tumor implantation. All mice were dead by day 25 post tumor implantation (treatment day 15).

5

[172] The combination of gemcitabine at 30mg/kg every 3 days and erlotinib 25mg/kg inhibited tumor growth by 86% ($p \leq 0.001$ versus vehicle control). There were no partial or complete regressions. This inhibition was not additive as it was not significantly better than either gemcitabine or erlotinib administered at 25% of the MTD. This combination was also not significantly better than erlotinib 100mg/kg or gemcitabine 120mg/kg.

10

[173] Combination activity erlotinib and gemcitabine in A549.

15 [174] At the end of this study (day 47 post tumor implantation, treatment day 19), erlotinib 100mg/kg significantly inhibited tumor growth by 87% ($p \leq 0.001$) (Figure 5). There were two partial regressions (16% and 7%). As in the previous studies, erlotinib 25mg/kg had suboptimal efficacy of 48% tumor growth inhibition ($p = 0.004$).

20 [175] Gemcitabine 120mg/kg significantly inhibited tumor growth by 75% ($p \leq 0.001$) with one partial regression (5%). Gemcitabine 30mg/kg inhibited tumor growth by 42% ($p = 0.001$). Because of toxicities in previous studies, gemcitabine and erlotinib were not combined at the high doses. Gemcitabine 30mg/kg and erlotinib 25mg/kg combined were well tolerated by all mice, with no significant weight loss or overall signs of toxicity. The combination significantly inhibited tumor growth by 103% ($p \leq 0.001$ versus vehicle control), with six partial regressions (range: 5%–67%). This tumor growth inhibition was additive, as it was significantly better than either gemcitabine or erlotinib administered at a quarter of the MTD ($p \leq 0.05$). The combination was not significantly better than erlotinib 100mg/kg, or gemcitabine 120mg/kg.

25

[176] Treatment-related effects on normal and tumor tissue.

[177] Necropsy in animals given monotherapy.

[178] In animals given erlotinib monotherapy, there were no changes in haematology parameters or clinical chemistry parameters (data not shown). There were treatment-related macroscopic changes in the skin. The mice had substantial reddening and crusting of the skin of the muzzle (Figure 7) that might have been due to the high level of expression of EGFR in the skin. These lesions were transient and dissipated with continued treatment. Treatment-related anti-tumor effects consisted of a mild decrease in Ki-67 proliferative index in the erlotinib 100mg/kg in both NSCLC xenograft tumor models (Figure 8). There was no significant difference in the frequency of apoptosis in tumor cells in the treated xenografts, and no clear effect on angiogenesis as measured by microvascular density (MVD) via immunohistochemical staining for the endothelial cell marker, CD31.

[179] Necropsy in animals given erlotinib/gemcitabine combination.

[180] For mice given erlotinib and gemcitabine at a quarter of the MTD, there were no significant findings in the major organ systems assessed histologically. Treatment-related effects on haematology and serum chemistry parameters were minimal. There was little evidence of treatment-related toxicity under the conditions of this study. Therefore, although the combination of erlotinib 25mg/kg plus gemcitabine 30mg/kg had clear antineoplastic effects, it did not appear to increase toxicity. Effects on proliferation in the combination group (assessed by Ki67 staining) were similar to those in erlotinib monotherapy-treated mice (Figure 8b).

[181] Discussion

[182] These results show that erlotinib, a potent, orally available and selective small-molecule inhibitor of HER1/EGFR, has strong antitumor activity in human NSCLC xenograft models expressing similar numbers of HER1/EGFR, as monotherapy and in combination with conventional chemotherapeutics.

[183] In the xenograft model H460a, it had an excellent dose-response relationship, and tumor concentration correlated well with plasma concentration.

[184] The two human NSCLC cell lines, when grown as subcutaneous tumors in

athymic mice, had different tumor growth kinetics, with a doubling time of 5 days for H460a and 10 days for A549. Erlotinib monotherapy at 100mg/kg significantly inhibited tumor growth in the H460a xenograft model.

5 [185] There was significant tumor-growth inhibition and partial remission with the gemcitabine/erlotinib combination, administered at 25% of the MTD, in the slow-growing A549 tumor (>100%). Tumor growth inhibition with erlotinib in combination with gemcitabine was significantly increased compared with erlotinib monotherapy ($p \leq 0.05$). In the faster-growing H460a tumor, there was substantial tumor growth
10 inhibition with the gemcitabine/erlotinib combination (86%) using a quarter of the MTD of either of the compounds. However, tumor growth inhibition with this combination was not significantly different from that with monotherapy. A549 is slow growing and therefore assumed to be more dependent on angiogenesis. Erlotinib is thought to be an indirect anti-angiogenic agent (Kerbel, R. and Folkman, J. (2002) Nat. Rev. Cancer
15 2(10):727–39), so it is not surprising that it has greater efficacy against A549. Erlotinib inhibits the binding of adenosine triphosphate (ATP) to the intracellular tyrosine kinase domain of HER1/EGFR, blocking receptor phosphorylation and associated downstream signalling (Moyer J.D. et al. (1997) Cancer Res. 57:4838–4848). The result is inhibition of cellular processes associated with tumor growth and progression, such as proliferation,
20 angiogenesis, metastasis and protection from apoptosis (Moyer J.D. et al. (1997) Cancer Res. 57:4838–4848). Unfortunately, anti-angiogenic effects were not detected by MVD in the tumors treated with erlotinib, possibly because the assay was not sensitive enough.

[186] In both NSCLC models, gemcitabine (30mg/kg) with erlotinib (25mg/kg),
25 administered at a quarter of the MTD, was well tolerated, with no or insignificant weight loss, suggesting potential significant quality of life benefits for patients, by maintaining efficacy with less risk of side effects. In contrast, the high-dose combination of erlotinib and conventional agents at their individual maximum tolerated doses was not tolerated. This may be related to the fact that supportive care cannot be used preclinically.

30

[187] Phase III trials of erlotinib in combination with gemcitabine and cisplatin, or with carboplatin and paclitaxel in humans with NSCLC have been disappointing since a conclusive survival benefit was not demonstrated. Nevertheless, the preclinical studies reported here have clearly shown that erlotinib in combination with chemotherapy has an
35 additive effect on inhibiting tumor growth. These findings support the need for further

examination of the effects of erlotinib in various clinical settings such as its sequential use with other chemotherapy agents, and in selected patient populations. In addition, HER1/EGFR is over expressed in numerous cancers, including head and neck, prostate, glioma, gastric, breast, cervical, pancreatic and ovarian cancer (Ciardiello, F and Tortora G. (2002) Expert Opin. Investig. Drugs 11:755–768); Salomon DS, et al. (1995) Crit. Rev. Oncol. Hematol. 19:183–232). Therefore, erlotinib in combination with gemcitabine may have efficacy benefits in other cancers with HER1/EGFR-expressing solid-cell tumors.

10 [188] In conclusion, in NSCLC, the antitumor activity of erlotinib in xenograft tumors with similar levels of EGFR expression is robust both as monotherapy and in combination with gemcitabine. Further research is needed to fully evaluate this promising new avenue in cancer treatment.

15 [189] **Incorporation by Reference**

[190] All patents, published patent applications and other references disclosed herein are hereby expressly incorporated herein by reference.

20 [191] **Equivalents**

[192] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the
25 scope of the following claims.

Table 1

Single-dose pharmacokinetics of erlotinib 20 and 100mg/kg in non-tumour bearing
5 female nu/nu athymic mice.

	20 mg/kg	100 mg/kg
C _{max} (ng/ml)	9100	24000
C _{max} /dose ([ng/ml]/[mg/kg])	455	240
T _{max} (h)	0.5–1	0.5–1
T _{last} (h)	8	24
AUC _{last} (h*ng/ml)	33500	196000
AUC _{last} /dose ([h*ng/ml]/[mg/kg])	1680	1960
CL/F (ml/min/kg)	7.6	8.0
λ_z (1/hour)	0.17	0.19
T _{1/2} (h)	4.1	4.0
MRT (h)	5.6	8.2
V _z /F (l/kg)	2.7	2.8

10 C_{max} = peak plasma concentration; T_{max} = time to peak plasma concentration; T_{last} = time of last measurable concentration; AUC last = area under the plasma concentration-time curve from time zero to time of last measurable concentration; CL/F = apparent clearance; λ_z = elimination rate constant; T_{1/2} = plasma terminal half-life; MRT = mean residence time; V_z/F = apparent volume of distribution.

Table 2

Maximum tolerated dose assessment in non-tumour bearing athymic nude mice treated for 14 days (n=5).

Compound	Dose (mg/kg)	Change in body Weight at end of Study (%)	Mortality
Vehicle control	0	0	0
Erlotinib in CMC/Tween	400	N/A	5
Erlotinib in CMC/Tween	200	N/A	5
Erlotinib in CMC/Tween	100	-1	0
Erlotinib in CMC/Tween	50	-1	0
Vehicle control	0	-1	0
Gemcitabine	150	-3	0
Gemcitabine	120	-1	0
Gemcitabine	90	-2	0
Gemcitabine	60	4	0
Gemcitabine	30	-3	0

5

N/A = not available; animals died before the end of the study.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition, in particular for use in cancer, comprising an EGFR
5 kinase inhibitor and gemcitabine, in a pharmaceutically acceptable carrier.
2. A pharmaceutical composition of claim 1, wherein the EGFR kinase inhibitor is erlotinib.
3. The pharmaceutical composition of claim 2, wherein the erlotinib in the composition is present as a hydrochloride salt.
- 10 4. The pharmaceutical composition of any one of claims 1 to 3, additionally comprising one or more other anti-cancer agents.
5. A method for manufacturing a medicament intended for treating tumors or tumor metastases, characterized in that an EGFR kinase inhibitor and gemcitabine are used.
6. The method of claim 5, wherein the medicament is intended for cancer.
- 15 7. The method of claim 5 or 6, wherein the EGFR kinase inhibitor and gemcitabine are contained in the same formulation.
8. The method of claim 5 or 6, wherein the EGFR kinase inhibitor and gemcitabine are contained in different formulations.
9. The method of any one of claims 5 to 8, wherein the EGFR kinase inhibitor and
20 gemcitabine are intended for administration to the patient by the same route.
10. The method of any one of claims 5 to 9, wherein the EGFR kinase inhibitor and gemcitabine are intended for administration to the patient by different routes.
11. The method of any one of claims 5 to 10, wherein the EGFR kinase inhibitor erlotinib is used.
- 25 12. The method of any one of claims 5 to 11, wherein erlotinib is intended for administration to the patient by parenteral or oral administration.
13. The method of any one of claims 5 to 12, wherein gemcitabine is intended for administration to the patient by parenteral administration.

14. The method of any one of claims 5 to 13, additionally comprising one or more other anti-cancer agents.
15. The method of any one of claims 5 to 14, wherein the other anti-cancer agents are selected from an alkylating agent, cyclophosphamide, chlorambucil, cisplatin, busulfan, melphalan, carmustine, streptozotocin, triethylenemelamine, mitomycin C, an anti-metabolite, methotrexate, etoposide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, capecitabine, dacarbazine, an antibiotic, actinomycin D, doxorubicin, daunorubicin, bleomycin, mithramycin, an alkaloid, vinblastine, paclitaxel, a glucocorticoid, dexamethasone, a corticosteroid, prednisone, a nucleoside enzyme inhibitors, hydroxyurea, an amino acid depleting enzyme, asparaginase, leucovorin, and a folic acid derivative.
16. A method of preparing a pharmaceutical composition useful for treating tumors or tumor metastases in a patient, comprising combining gemcitabine with an EGFR kinase inhibitor.
17. A method according to claim 16, wherein the EGFR kinase inhibitor is erlotinib.
18. The method of claim 17, further comprising combining a pharmaceutically acceptable carrier with the gemcitabine and erlotinib.
19. A kit comprising a container comprising gemcitabine and an EGFR kinase inhibitor.
20. The kit of claim 19, further comprising a sterile diluent.
21. The kit of claim 19, wherein the EGFR kinase inhibitor is erlotinib.
22. The kit of any one of claims 19 to 21, further comprising a package insert comprising printed instructions directing the use of a combined treatment of gemcitabine and erlotinib to a patient as a method for treating tumors, tumor metastases or other cancers in a patient.
23. The composition according to claim 1, additionally comprising one or more other anti-cancer agents.
24. A composition in accordance with claim 23, wherein said other anti-cancer agent is a member selected from the group consisting of alkylating drugs, antimetabolites, microtubule inhibitors, podophyllotoxins, antibiotics, nitrosoureas, hormone therapies, kinase inhibitors, activators of tumor cell apoptosis, and antiangiogenic agents.

25. A method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) an effective first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof; and (ii) an effective second amount of gemcitabine.
- 5 26. A method for the treatment of cancer, comprising administering to a subject in need of such treatment (i) a sub-therapeutic first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof; and (ii) a sub-therapeutic second amount of gemcitabine.
27. A method for the treatment of cancer according to claim 25 or 26, wherein the EGFR
10 kinase inhibitor is erlotinib.
28. The method of claim 5, wherein the tumors or tumor metastases to be treated are colorectal tumors or tumor metastases.
29. A pharmaceutical composition, in particular for use in cancer, comprising (i) an effective first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt
15 thereof; and (ii) an effective second amount of gemcitabine.
30. A pharmaceutical composition, in particular for use in cancer, comprising (i) a sub-therapeutic first amount of an EGFR kinase inhibitor, or a pharmaceutically acceptable salt thereof; and (ii) a sub-therapeutic second amount of gemcitabine.
31. A pharmaceutical composition according to claim 29 or 30, wherein the EGFR kinase
20 inhibitor is erlotinib.
32. An EGFR kinase inhibitor and gemcitabine for use as medicament, in particular for use in cancer.
33. Erlotinib and gemcitabine for use as medicament, in particular for use in cancer.
34. Use of an EGFR kinase inhibitor and gemcitabine for the manufacture of a
25 medicament for treating tumors or tumor metastases.
35. Use according to claim 34, wherein the EGFR kinase inhibitor is erlotinib.
36. The novel compounds, processes, pharmaceutical compositions, methods and uses as described herein.


Fig. 1


Fig. 2


Fig. 3


Fig. 4

Fig. 5





Fig. 6

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/005735

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/513 A61K31/517 A61K31/5377 A61K31/519 A61K31/4706
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RATAIN ET AL.: "Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumours." PROC AM SOC CLIN ONCOL, vol. 21, no. Abs2115, 2002, XP009053760 the whole document	1-36
X	Phase III Tarceva trial in NSCLC completes enrollment. 'September 18, 2002!'. DailyDrugNews.com XP001207335 abstract	1-36
	----- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

15 September 2005

Date of mailing of the international search report

05/10/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornich, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/005735

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KRAWCZYK PAWEL ET AL: "Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer." ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA. SECTIO D: MEDICINA. 2003, vol. 58, no. 1, 2003, pages 113-117, XP009053758 ISSN: 0066-2240 page 115, paragraph 4 'Summary'	1-36
X	HIGGINS BRIAN ET AL: "Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models" ANTI-CANCER DRUGS, vol. 15, no. 5, June 2004 (2004-06), pages 503-512, XP009053757 ISSN: 0959-4973 the whole document	1-36
X	WO 01/34574 A (OSI PHARMACEUTICALS, INC) 17 May 2001 (2001-05-17) page 3 page 43, line 13 page 43, line 1 - line 3 claims 14-16	1-36
X	GIACCONE G ET AL: "Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1" JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 22, no. 5, 1 March 2004 (2004-03-01), pages 777-784, XP002334312 ISSN: 0732-183X the whole document	1-36
X	HAMMOND L A: "PHARMACOKINETIC EVALUATION OF GEFITINIB WHEN ADMINISTERED WITH CHEMOTHERAPY" CLINICAL LUNG CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 5, no. SUPPL 1, September 2003 (2003-09), pages S18-S20, XP009052596 ISSN: 1525-7304 in particular page S20 - page S21	1,5-10, 13-16, 19,20, 23-26, 28-30, 32,34,36
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/005735

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 02/45653 A (UAB RESEARCH FOUNDATION) 13 June 2002 (2002-06-13)</p> <p>page 4 page 6 claims</p>	<p>1,5-10, 13,16, 19,20, 25,26, 28-30, 32,34,36</p>
X	<p>WO 02/39121 A (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; FIDLER, ISIAH, J; B) 16 May 2002 (2002-05-16)</p> <p>page 16 page 46, paragraph 2 tables 3-5 page 56 - page 58</p>	<p>1,5-10, 13,16, 19,20, 25,26, 28-30, 32,34,36</p>
X	<p>WO 2004/014386 A (WARNER-LAMBERT COMPANY LLC; ELLIOTT, WILLIAM, LEON; FRY, DAVID, WILLIA) 19 February 2004 (2004-02-19)</p> <p>page 8, line 1 - line 2 page 10 page 12, paragraph 2 example 1</p>	<p>1,5-10, 13,16, 19-22, 25,26, 29,30, 32,34,36</p>
X	<p>SRIDHAR S S ET AL: "Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer" LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 4, no. 7, July 2003 (2003-07), pages 397-406, XP004809825 ISSN: 1470-2045 the whole document</p>	<p>1-36</p>
P,X	<p>GATZEMEIER ET AL.: "Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer" PROC AM SOC CLIN ONCOL, vol. 23:617, no. Abs7010, June 2004 (2004-06), XP009053761 the whole document</p>	<p>1-36</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/005735

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>BURGOS FUSTER L M ET AL: "Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes"</p> <p>CLINICAL LUNG CANCER 2004 UNITED STATES, vol. 6, no. SUPPL. 1, 2004, pages S24-S29, XP009053756</p> <p>ISSN: 1525-7304</p> <p>the whole document</p> <p>-----</p>	1-36

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/005735

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 25-28 and 36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/005735

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0134574	A	17-05-2001	AU 1762101 A	06-06-2001
			BG 106761 A	31-01-2003
			BR 0015544 A	23-07-2002
			CA 2389333 A1	17-05-2001
			CN 1414954 A	30-04-2003
			CZ 20022019 A3	14-05-2003
			EA 5318 B1	30-12-2004
			EP 1233948 A1	28-08-2002
			HR 20020388 A2	30-06-2004
			HU 0302665 A2	29-12-2003
			JP 2003523949 T	12-08-2003
			MA 25570 A1	01-10-2002
			NO 20021910 A	01-07-2002
			NZ 518406 A	30-01-2004
			PL 355235 A1	05-04-2004
			SK 5812002 A3	10-09-2002
WO 0245653	A	13-06-2002	AU 3948602 A	18-06-2002
WO 0239121	A	16-05-2002	AU 3657202 A	21-05-2002
			CA 2427622 A1	16-05-2002
			EP 1332368 A2	06-08-2003
			JP 2004529315 T	24-09-2004
WO 2004014386	A	19-02-2004	AU 2003249450 A1	25-02-2004
			BR 0313470 A	21-06-2005
			CA 2494270 A1	19-02-2004
			EP 1549320 A1	06-07-2005